Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2026

Percentage of Net Product Sales and Accounts Receivable Balance

The following table includes the percentage of net product sales and accounts receivable balances for our three major Customers, each of which comprised 10% or more of our product sales:


	Net Product Sales			Accounts Receivable
	Three Months Ended March 31, 2026			As of March 31, 2026
Customer A		36.4	%		36.2	%
Customer B		36.2	%		36.1	%
Customer C		25.4	%		27.4	%
Total		98.0	%		99.7	%

Schedule of Disaggregated Net Product Sales

The following table provides disaggregated net product sales (in thousands):


	Three Months Ended March 31,
	2026		2025
CINVANTI net product sales	$	20,535	$	25,742
SUSTOL net product sales		547		2,859
ZYNRELEF net product sales		10,235		8,042
APONVIE net product sales		3,394		2,260
Total net product sales	$	34,711	$	38,903

Summary of Activity to Product Returns, Distributor Fees and Discounts, Rebates and Administrative Fees

The following table provides a summary of activity with respect to our product returns, distributor fees and discounts, rebates and administrative fees, which are included in other accrued liabilities on the condensed consolidated balance sheets (in thousands):


	Product Returns			Distributor Fees			Discounts, Rebates and Administrative Fees			Total
Balance at December 31, 2025	$	4,515		$	7,328		$	34,152		$	45,995
Provision		94			8,183			52,364		$	60,641
Payments/credits		(382	)		(9,087	)		(52,529	)	$	(61,998	)
Balance at March 31, 2026	$	4,227		$	6,424		$	33,987		$	44,638

Schedule of Numerator (Earnings or Loss) and Denominator (Shares) to Calculate the Basic and Diluted Earnings Per Share

the computations of the numerator (earnings or loss) and denominator (shares) to calculate the basic and diluted earnings per share amounts presented in the accompanying condensed consolidated statements of operations and comprehensive income (loss) are as follows (in thousands, except per share amounts):


	Three Months Ended March 31, 2025
	Income		Shares
Basic:
Net income	$	2,635		153,490

Earnings per share, basic	$	0.02

Diluted:
Net income	$	2,635		153,490
Effect of dilutive securities:
Stock options outstanding		—		29,462
Restricted stock units outstanding		—		3,852
Warrants outstanding		—		298
Shares of common stock underlying convertible notes outstanding		—		9,819
Net income, diluted	$	2,635		196,921

Earnings per share, diluted	$	0.01

Common Stock Equivalents Excluded From Computation of Net Loss Per Share

Because we have incurred a net loss for the three months ended March 31, 2026, the following common stock equivalents were not included in the computation of net loss per share because their effect would be anti-dilutive (in thousands):


	As of March 31,
	2026
Stock options outstanding		28,512
Restricted stock units outstanding		11,340
Warrants outstanding		298
Series A Preferred Stock convertible to common shares		700
Shares of common stock underlying convertible notes outstanding		19,444

For the three months ended March 31, 2025, we recognized net income. Accordingly, the computations of the numerator (earnings or loss) and denominator (shares) to calculate the basic and diluted earnings per share amounts presented in the accompanying condensed consolidated statements of operations and comprehensive income (loss) are as follows (in thousands, except per share amounts):


	Three Months Ended March 31, 2025
	Income		Shares
Basic:
Net income	$	2,635		153,490

Earnings per share, basic	$	0.02

Diluted:
Net income	$	2,635		153,490
Effect of dilutive securities:
Stock options outstanding		—		29,462
Restricted stock units outstanding		—		3,852
Warrants outstanding		—		298
Shares of common stock underlying convertible notes outstanding		—		9,819
Net income, diluted	$	2,635		196,921

Earnings per share, diluted	$	0.01